--- title: "NUTRIBAND INC C/WTS (TO PUR COM) | 10-K: FY2026 Revenue: USD 2.037 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/284646143.md" datetime: "2026-04-29T21:16:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284646143.md) - [en](https://longbridge.com/en/news/284646143.md) - [zh-HK](https://longbridge.com/zh-HK/news/284646143.md) generator: "portal-rs" --- # NUTRIBAND INC C/WTS (TO PUR COM) | 10-K: FY2026 Revenue: USD 2.037 M Revenue: As of FY2026, the actual value is USD 2.037 M. EPS: As of FY2026, the actual value is USD -2.58. EBIT: As of FY2026, the actual value is USD -8.367 M. #### Segment Revenue - **Total Revenue:** Total revenue was $2,036,651 for the year ended January 31, 2026, a decrease from $2,139,537 in the prior year ended January 31, 2025. - **Pocono Pharmaceuticals Segment Revenue:** This segment generated $2,036,651 in 2026 and $2,139,537 in 2025, with revenue remaining relatively constant year-over-year. - **4P Therapeutics Segment Revenue:** This segment generated no revenue from contract research and development services in both 2026 and 2025. - **Revenue Category:** All revenue for both years was categorized as “Sale of goods,” with no revenue from “Services.” - **Geographic Revenue:** United States revenue was $2,029,021 in 2026 and $2,139,537 in 2025, while foreign revenue was $7,630 in 2026 and $0 in 2025. #### Operational Metrics - **Gross Profit:** Total gross profit was $566,308 for the year ended January 31, 2026, down from $743,317 in the prior year, primarily due to lower margins on tape sales. - **Pocono Pharmaceuticals Segment Gross Profit:** This segment generated gross profits of $566,308 in 2026 and $743,317 in 2025. - **4P Therapeutics Segment Gross Profit:** This segment generated $0 in gross profit for both 2026 and 2025. - **Operating Expenses:** - **Selling, General and Administrative (SG&A) Expenses:** Increased to $6,993,140 in 2026 from $4,313,810 in 2025, mainly due to an increase in equity-based expenses. - **Research and Development (R&D) Expenses:** Decreased to $1,891,129 in 2026 from $3,119,134 in 2025, mainly due to a reduction in labor costs. - **Goodwill and Intangibles Impairment Charge:** The company incurred no charge in 2026, compared to $3,595,216 in 2025. - **Total Costs and Expenses:** Were $10,354,612 in 2026, down from $12,424,380 in 2025. - **Loss from Operations:** Was - $8,317,961 for the year ended January 31, 2026, an improvement from - $10,284,843 in the prior year. - **Other Income (Expense):** - **Other Income:** Was $110,864 in 2026, a decrease from $191,669 in 2025. - **Loss on Extinguishment of Debt:** The company recorded no loss in 2026, compared to - $368,036 in 2025. - **Interest Expense:** Was $22,535 in 2026, slightly up from $21,407 in 2025. - **Net Loss:** The net loss was - $8,229,632 for the year ended January 31, 2026, an improvement compared to a net loss of - $10,482,617 for the year ended January 31, 2025. - **Net Loss Available to Common Shareholders:** After a preferred stock dividend of - $21,814,166, the net loss available to common shareholders was - $30,043,798 or - $2.58 per share (basic and diluted) in 2026, compared to - $10,482,617 or - $0.99 per share (basic and diluted) in 2025. #### Cash Flow - **Operating Cash Flow:** Net cash used in operating activities was - $5,134,630 for the year ended January 31, 2026, compared to - $4,626,564 for the year ended January 31, 2025. Principal adjustments in 2026 included depreciation and amortization of $193,797 and stock-based compensation of $2,633,996. - **Free Cash Flow:** The report does not explicitly present Free Cash Flow as a distinct metric. #### Unique Metrics - **Research and Development Spending for Aversa Fentanyl:** The company incurred $1,891,129 in R&D expenses for its Aversa Fentanyl product in 2026, compared to $3,119,134 in 2025. As of January 31, 2026, $4.7 million had been incurred under the agreement with Kindeva Drug Delivery, with an estimated $2.5 million required to complete development through NDA submission for the current workplan. An additional $3.0 million milestone payment is due to Kindeva upon FDA approval. #### Outlook / Guidance Management believes that sufficient funds will be generated from operations to fund operations for one year from the filing date, indicating improved operations and ability to continue as a going concern. The company plans to continue relying on sales of securities and debt issuance to support operations and fund the development of Aversa products, with an estimated $13 million required for Aversa Fentanyl R&D for FDA approval. The company intends to seek a small business waiver for the $4,682,003 standard NDA application fee for its first product in fiscal year 2026, with an annual program fee of $442,213 per prescription drug product after approval. ### Related Stocks - [NTRBW.US](https://longbridge.com/en/quote/NTRBW.US.md) ## Related News & Research - [$1000 Invested In Watts Water Technologies 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/297827427.md) - [YieldMax Memory & Storage Portfolio Option Inc ETF declares $0.4155 dividend](https://longbridge.com/en/news/298352301.md) - [PROVIDENT FINANCIAL HOLDINGS INC FY 2026: Revenue $36.3M, EPS $1.03— 10-K Summary](https://longbridge.com/en/news/297821698.md) - [YieldMax Strat Metals & Mining Portfolio Opt Inc ETF declares $0.2311 dividend](https://longbridge.com/en/news/298351624.md) - [Legal & General Group Plc Takes Position in TIC Solutions, Inc $TIC](https://longbridge.com/en/news/298279555.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**